Switch to
More onapp

How to use scorecard? Learn more

Glenmark Pharmaceuticals Ltd

GLENMARK
Health CarePharmaceuticals
MidcapWith a market cap of ₹29,757 cr, stock is ranked 240
High RiskStock is 3.39x as volatile as Nifty
1,047.254.55 (-0.43%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Bad

The stock is overpriced and in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹29,757 cr, stock is ranked 240
High RiskStock is 3.39x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
-41.81
PB RatioPB Ratio
3.02
Dividend YieldDiv. Yield
0.24%
Sector PESector PE
52.23
Sector PBSector PB
5.97
Sector Div YldSctr Div Yld
0.56%

Forecast & RatingsDetailed Forecast 

40%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

Brands

Glenmark Pharma

Pharmaceutical company

Investor PresentationView older 

Sep 21, 2023

PDF
View Older Presentations

Brands

Glenmark Pharma

Pharmaceutical company

Financial TrendFinancial statements 

202020212022202310.8311.0412.4713.310.780.970.940.30
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.29%

See detailed holdings

Recent EventsAll events 

Credit Rating 
Announced OnMar 20, 2024

Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating | Download

Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating | Download

Credit Rating 
Announced OnMar 13, 2024

Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating | Download

Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating | Download

Cash Dividend 
Ex. DateSep 18, 2023

Final • Div/Share: ₹ 2.5

See all events